Výsledky vyhledávání - "Anasheh Shamirian"

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

Publikováno v: J Clin Oncol

PURPOSE 131I-metaiodobenzylguanidine (MIBG) is an active radiotherapeutic for neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens was likely associated with the highest true response rate. PATIENTS AND METHODS Pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5465588083dc929da824e7729c79092
https://europepmc.org/articles/PMC8547934/

Zobrazit plný text záznamu

Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

Autor: Thomas Cash, Araz Marachelian, Steven G. DuBois, Yueh-Yun Chi, Susan G. Groshen, Anasheh Shamirian, Alina C Stout, Margaret E Macy, Navin R. Pinto, Ami Vijay Desai, Paul M. Sondel, Shahab Asgharzadeh, Brian D. Weiss, Yael P. Mosse, Katherine K. Matthay, Julie R. Park, Kelly C. Goldsmith

Publikováno v: Journal of Clinical Oncology. 40:10038-10038

10038 Background: 131I-metaiodobenzylguanidine (MIBG) is one of the most active salvage therapies for patients with relapsed or refractory (R/R) high-risk neuroblastoma (HRNB). Preclinical neuroblastoma studies show cooperative effects when radiation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::57a39d72185617f7f2b2852ee2c0fd7d
https://doi.org/10.1200/jco.2022.40.16_suppl.10038

Zobrazit plný text záznamu

Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium

Publikováno v: Journal of Clinical Oncology. 38:10500-10500

10500 Background: 131I-metaiodobenzylguanidine (MIBG) remains one of the most active agents for neuroblastoma. It is not clear if putative radiation sensitizers improve upon this activity. The primary aim of this trial was to identify the MIBG treatm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03aa58e1bd415d58a64b1e0e572ba9f8
https://doi.org/10.1200/jco.2020.38.15_suppl.10500

Zobrazit plný text záznamu

NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma

Autor: Kangning Liu, Charlotte Hasenauer, Michael D. Hogarty, Elizabeth Bruckheimer, Eugene W. Gerner, Andrea T. Flynn, Michelle Haber, Murray D. Norris, Katherine K. Matthay, Susan Groshen, Anasheh Shamirian, David S. Ziegler, Araz Marachelian

Publikováno v: Journal of Clinical Oncology. 36:10558-10558

10558Background: MYC drives polyamine expansion to support its oncogenic functions. Ornithine decarboxylase (Odc) is a direct MYC target that is rate-limiting for polyamine synthesis, and is itself...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::08adf3bb445a885e5398f18dd94ed868
https://doi.org/10.1200/jco.2018.36.15_suppl.10558

Zobrazit plný text záznamu

Inter-operator and inter-device agreement and reliability of the SEM Scanner

Autor: Kindah Jaradeh, Shannon L. Rhodes, Marta Clendenin, Anasheh Shamirian

Publikováno v: Journal of tissue viability. 24(1)

Objective: The SEM Scanner is a medical device designed for use by healthcare providers as part of pressure ulcer prevention programs. The objective of this study was to evaluate the inter-rater and inter-device agreement and reli- ability of the SEM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8782213c7f56873558b3b1b722310ce
https://pubmed.ncbi.nlm.nih.gov/25682271

Zobrazit plný text záznamu